Last reviewed · How we verify
Zagreb2-1-1
Zagreb2-1-1 is a Biologic drug developed by Beijing Center for Disease Control and Prevention. It is currently FDA-approved.
Zagreb2-1-1 is an antibody that inhibits programmed cell death 1 ligand 1. It is being studied in a clinical trial for conditions such as rabies vaccine allergy and vaccination adverse events.
At a glance
| Generic name | Zagreb2-1-1 |
|---|---|
| Sponsor | Beijing Center for Disease Control and Prevention |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zagreb2-1-1 CI brief — competitive landscape report
- Zagreb2-1-1 updates RSS · CI watch RSS
- Beijing Center for Disease Control and Prevention portfolio CI
Frequently asked questions about Zagreb2-1-1
What is Zagreb2-1-1?
Who makes Zagreb2-1-1?
What development phase is Zagreb2-1-1 in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing